CA3109100A1 - Arginase inhibitors and methods of use thereof - Google Patents
Arginase inhibitors and methods of use thereof Download PDFInfo
- Publication number
- CA3109100A1 CA3109100A1 CA3109100A CA3109100A CA3109100A1 CA 3109100 A1 CA3109100 A1 CA 3109100A1 CA 3109100 A CA3109100 A CA 3109100A CA 3109100 A CA3109100 A CA 3109100A CA 3109100 A1 CA3109100 A1 CA 3109100A1
- Authority
- CA
- Canada
- Prior art keywords
- aza
- oxa
- boraspiro
- dodecan
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721113P | 2018-08-22 | 2018-08-22 | |
| US62/721,113 | 2018-08-22 | ||
| PCT/EP2019/072341 WO2020038983A1 (en) | 2018-08-22 | 2019-08-21 | Arginase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3109100A1 true CA3109100A1 (en) | 2020-02-27 |
Family
ID=67742403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3109100A Pending CA3109100A1 (en) | 2018-08-22 | 2019-08-21 | Arginase inhibitors and methods of use thereof |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11952392B2 (enExample) |
| EP (2) | EP4371614A3 (enExample) |
| JP (1) | JP7441210B2 (enExample) |
| KR (1) | KR102668252B1 (enExample) |
| CN (1) | CN112584900B (enExample) |
| AU (1) | AU2019323663B2 (enExample) |
| CA (1) | CA3109100A1 (enExample) |
| CL (1) | CL2021000430A1 (enExample) |
| DK (1) | DK3840837T3 (enExample) |
| EA (1) | EA202190532A1 (enExample) |
| ES (1) | ES2980252T3 (enExample) |
| FI (1) | FI3840837T3 (enExample) |
| HR (1) | HRP20240694T1 (enExample) |
| HU (1) | HUE066903T2 (enExample) |
| IL (1) | IL280924B2 (enExample) |
| LT (1) | LT3840837T (enExample) |
| MA (1) | MA53427B1 (enExample) |
| MX (1) | MX2021002042A (enExample) |
| PL (1) | PL3840837T3 (enExample) |
| PT (1) | PT3840837T (enExample) |
| RS (1) | RS65608B1 (enExample) |
| SG (1) | SG11202101618PA (enExample) |
| SI (1) | SI3840837T1 (enExample) |
| SM (1) | SMT202400221T1 (enExample) |
| WO (1) | WO2020038983A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| MY206577A (en) * | 2019-02-08 | 2024-12-24 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| EP4239652A4 (en) | 2020-12-25 | 2024-06-05 | Sumitomo Riko Company Limited | Electrically conductive composition, sheet-form flexible electrode using same, and method for producing said electrode |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560978B1 (en) | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| AU2016281620B2 (en) * | 2015-06-23 | 2021-07-22 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| US11291674B2 (en) * | 2016-11-08 | 2022-04-05 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| WO2018119440A1 (en) | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| SG11202007739XA (en) | 2018-02-17 | 2020-09-29 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| US12215116B2 (en) | 2018-03-13 | 2025-02-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| WO2019205979A1 (zh) | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
-
2019
- 2019-08-21 MA MA53427A patent/MA53427B1/fr unknown
- 2019-08-21 PL PL19758683.7T patent/PL3840837T3/pl unknown
- 2019-08-21 SI SI201930758T patent/SI3840837T1/sl unknown
- 2019-08-21 RS RS20240642A patent/RS65608B1/sr unknown
- 2019-08-21 CA CA3109100A patent/CA3109100A1/en active Pending
- 2019-08-21 EA EA202190532A patent/EA202190532A1/ru unknown
- 2019-08-21 KR KR1020217007915A patent/KR102668252B1/ko active Active
- 2019-08-21 EP EP24162089.7A patent/EP4371614A3/en active Pending
- 2019-08-21 FI FIEP19758683.7T patent/FI3840837T3/fi active
- 2019-08-21 CN CN201980055111.3A patent/CN112584900B/zh active Active
- 2019-08-21 ES ES19758683T patent/ES2980252T3/es active Active
- 2019-08-21 HR HRP20240694TT patent/HRP20240694T1/hr unknown
- 2019-08-21 IL IL280924A patent/IL280924B2/en unknown
- 2019-08-21 WO PCT/EP2019/072341 patent/WO2020038983A1/en not_active Ceased
- 2019-08-21 EP EP19758683.7A patent/EP3840837B1/en active Active
- 2019-08-21 PT PT197586837T patent/PT3840837T/pt unknown
- 2019-08-21 JP JP2021509794A patent/JP7441210B2/ja active Active
- 2019-08-21 DK DK19758683.7T patent/DK3840837T3/da active
- 2019-08-21 AU AU2019323663A patent/AU2019323663B2/en active Active
- 2019-08-21 SM SM20240221T patent/SMT202400221T1/it unknown
- 2019-08-21 LT LTEPPCT/EP2019/072341T patent/LT3840837T/lt unknown
- 2019-08-21 US US17/269,569 patent/US11952392B2/en active Active
- 2019-08-21 HU HUE19758683A patent/HUE066903T2/hu unknown
- 2019-08-21 MX MX2021002042A patent/MX2021002042A/es unknown
- 2019-08-21 SG SG11202101618PA patent/SG11202101618PA/en unknown
-
2021
- 2021-02-19 CL CL2021000430A patent/CL2021000430A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019323663B2 (en) | Arginase inhibitors and methods of use thereof | |
| JP7699171B2 (ja) | アルギナーゼインヒビタ及びその使用方法 | |
| EP3921033B1 (en) | Arginase inhibitors and methods of use thereof | |
| HK40110939A (en) | Arginase inhibitors and methods of use thereof | |
| HK40055578B (en) | Arginase inhibitors and methods of use thereof | |
| HK40055578A (en) | Arginase inhibitors and methods of use thereof | |
| EA042333B1 (ru) | Ингибиторы аргиназы и способы их применения | |
| HK40042067A (en) | Arginase inhibitors and methods of use thereof | |
| HK40042067B (en) | Arginase inhibitors and methods of use thereof | |
| HK40065571A (en) | Arginase inhibitors and methods of use thereof | |
| HK40065571B (en) | Arginase inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240813 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240813 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241118 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241125 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241125 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241125 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241125 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250319 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250724 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250827 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251002 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260204 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260204 |